Quality of Life (QoL) and care pathway in patients with durable response to Immune Checkpoint Inhibitors (ICI-DR) for advanced or metastatic melanoma: QUALICI study
Background: Immune checkpoint inhibitors (ICIs) have significantly improved the prognosis of advanced or metastatic melanoma in recent years, with patients experiencing durable responses to treatment. These patients face specific QoL challenges. The QUALICI study aimed to assess patients’ QoL, their experiences, and expectations about QoL management.
Authors
- V. Moreau-Mallet
- N. Texier
- N. Girard
- H. Lemasson (ORCID: https://orcid.org/0000-0002-9656-2432)
- Charlotte Robert (ORCID: https://orcid.org/0000-0001-8838-1343)
- M. Chartier
- Jean-François Bonastre (ORCID: https://orcid.org/0000-0001-7741-3346)
- Gilliosa Spurrier
- S. Hervy
- S. Micheliza
- M. Coint Bavarot
Institutions
- Inserm (FR)
- Université Paris-Saclay (FR)
- Institut Gustave Roussy (FR)
- La Ligue Contre le Cancer (FR)
- Bristol-Myers Squibb (France) (FR)
- Institut du Thorax (FR)
Publication Details
- Journal
- EJC Skin Cancer
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1016/j.ejcskn.2025.100538
- Primary Topic
- Cutaneous Melanoma Detection and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00